Page 227 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

206 PART 3 Therapeutic Modalities for the Cancer Patient

301. Vail DM, von Euler H, Rusk AW, et al.: A randomized trial inves- 323. Chen GL, Yang L, Rowe TC, et al.: Nonintercalative antitumor
tigating the efficacy and safety of water soluble micellar paclitaxel drugs interfere with the breakage-reunion reaction of mammalian
(Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell DNA topoisomerase II, J Biol Chem 259:13560–13566, 1984.
VetBooks.ir 302. Kim J, Doerr M, Kitchell BE: Exploration of paclitaxel (taxol) as 324. Long BH, Musial ST, Brattain MG: Single- and double-strand DNA
tumors in dogs, J Vet Intern Med 26:598–607, 2012.
breakage and repair in human lung adenocarcinoma cells exposed to
a treatment for malignant tumors in cats: a descriptive case series,
etoposide and teniposide, Cancer Res 45:3106–3112, 1985.
J Feline Med Surg 17:186–190, 2015. 325. Sullivan DM, Latham MD, Ross WE: Proliferation-dependent
303. Simon D, Schoenrock D, Baumgartner W, et al.: Postoperative topoisomerase II content as a determinant of antineoplastic drug
adjuvant treatment of invasive malignant mammary gland tumors action in human, mouse, and chinese hamster ovary cells, Cancer
in dogs with doxorubicin and docetaxel, J Vet Intern Med 20:1184– Res 47:3973–3979, 1987.
1190, 2006. 326. Flory AB, Rassnick KM, Balkman CE, et al.: Oral bioavailability
304. Shiu KB, McCartan L, Kubicek L, et al.: Intravenous administra- of etoposide after administration of a single dose to tumor-bearing
tion of docetaxel to cats with cancer, J Vet Intern Med 25:916–919, dogs, Am J Vet Res 69:1316–1322, 2008.
2011. 327. Pommier YG, Goldwasser F, Strumberg D: Topoisomerase II
305. McEntee MC, Rassnick KM, Bailey DB, et al.: Phase I and phar- inhibitors: epipodophyllotoxins, acridines, ellipticines, and bis-
macokinetic evaluation of the combination of orally administered dioxopiperazines. In Chabner BA, Longo DL, editors: cancer che-
docetaxel and cyclosporin a in tumor-bearing cats, J Vet Intern Med motherapy & biotherapy: principles and practice, ed 3, Philadelphia,
20:1370–1375, 2006. 2001, Lippincott Williams & Wilkins, pp 538–578.
306. McEntee MC, Rassnick KM, Lewis LD, et al.: Phase I and phar- 328. Baxter JD, Harris AW, Tomkins GM, et al.: Glucocorticoid recep-
macokinetic evaluation of the combination of orally administered tors in lymphoma cells in culture: relationship to glucocorticoid
docetaxel and cyclosporin a in tumor-bearing dogs, Am J Vet Res killing activity, Science 171:189–191, 1971.
67:1057–1062, 2006. 329. Greenstein S, Ghias K, Krett NL, et al.: Mechanisms of glucocorti-
307. Waite A, Balkman C, Bailey D, et al.: Phase II study of oral coid-mediated apoptosis in hematological malignancies, Clin Can-
docetaxel and cyclosporine in canine epithelial cancer, Vet Comp cer Res 8:1681–1694, 2002.
Oncol 12:160–168, 2014. 330. Moalli PA, Rosen ST: Glucocorticoid receptors and resistance
308. Correia JJ: Effects of antimitotic agents on tubulin-nucleotide to glucocorticoids in hematologic malignancies, Leuk Lymphoma
interactions, Pharmacol Ther 52:127–147, 1991. 15:363–374, 1994.
309. Wilson L, Jordan MA, Morse A, et al.: Interaction of vinblastine 331. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, et al.:
with steady-state microtubules in vitro, J Mol Biol 159:125–149, Adducts of the antitumor drug cis-diamminedichloroplatinum(II)
1982. with DNA: formation, identification, and quantitation, Biochemis-
310. Bruchovsky N, Owen AA, Becker AJ, et al.: Effects of vinblastine try 24:707–713, 1985.
on the proliferative capacity of l cells and their progress through the 332. Zwelling LA, Anderson T, Kohn KW: DNA-protein and DNA
division cycle, Cancer Res 25:1232–1237, 1965. interstrand cross-linking by cis- and trans-platinum(II) diammin-
311. Tucker RW, Owellen RJ, Harris SB: Correlation of cytotoxicity edichloride in l1210 mouse leukemia cells and relation to cytotox-
and mitotic spindle dissolution by vinblastine in mammalian cells, icity, Cancer Res 39:365–369, 1979.
Cancer Res 37:4346–4351, 1977. 333. Reed E, Kohn KW, Chabner BA, et al.: Platinum analogues. Cancer
312. Creasey WA, Marsh JC: Metabolism of vinblastine (VBL) in the chemotherapy: principles and practice, Philadelphia, 1990, JB Lip-
dog, Proc Am Assoc Cancer Res 14:57, 1973 (abstract). pincott Co., pp 465–490.
313. Arnold EJ, Childress MO, Fourez LM, et al.: Clinical trial of vin- 334. Calvert AH, Newell DR, Gumbrell LA, et al.: Carboplatin dosage:
blastine in dogs with transitional cell carcinoma of the urinary prospective evaluation of a simple formula based on renal function,
bladder, J Vet Intern Med 25:1385–1390, 2011. J Clin Oncol 7:1748–1756, 1989.
314. Lenz JA, Robat CS, Stein TJ: Vinblastine as a second rescue for the 335. Bailey DB, Rassnick KM, Erb HN, et al.: Effect of glomerular fil-
treatment of canine multicentric lymphoma in 39 cases (2005 to tration rate on clearance and myelotoxicity of carboplatin in cats
2014), J Small Anim Pract 57:429–434, 2016. with tumors, Am J Vet Res 65:1502–1507, 2004.
315. Krick EL, Cohen RB, Gregor TP, et al.: Prospective clinical trial 336. Knapp DW, Richardson RC, DeNicola DB, et al.: Cisplatin toxic-
to compare vincristine and vinblastine in a cop-based protocol for ity in cats, J Vet Intern Med 1:29–35, 1987.
lymphoma in cats, J Vet Intern Med 27:134–140, 2013. 337. Knapp DW, Henry CJ, Widmer WR, et al.: Randomized trial of
316. Vickery KR, Wilson H, Vail DM, et al.: Dose-escalating vinblas- cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with
tine for the treatment of canine mast cell tumour, Vet Comp Oncol transitional cell carcinoma of the urinary bladder, J Vet Intern Med
6:111–119, 2008. 27:126–133, 2013.
317. Serra Varela JC, Pecceu E, Handel I, et al.: Tolerability of a rapid- 338. Barabas K, Milner R, Lurie D, et al.: Cisplatin: a review of toxicities
escalation vinblastine-prednisolone protocol in dogs with mast cell and therapeutic applications, Vet Comp Oncol 6:1–18, 2008.
tumours, Vet Med Sci 2:266–280, 2016. 339. Allstadt SD, Rodriguez CO, Boostrom B, et al.: Randomized phase
318. Grant IA, Rodriguez CO, Kent MS, et al.: A phase II clinical trial III trial of piroxicam in combination with mitoxantrone or car-
of vinorelbine in dogs with cutaneous mast cell tumors, J Vet Intern boplatin for first-line treatment of urogenital tract transitional cell
Med 22:388–393, 2008. carcinoma in dogs, J Vet Intern Med 29:261–267, 2015.
319. Poirier VJ, Burgess KE, Adams WM, et al.: Toxicity, dosage, and 340. Wouda RM, Borrego J, Keuler NS, et al.: Evaluation of adjuvant
efficacy of vinorelbine (navelbine) in dogs with spontaneous neo- carboplatin chemotherapy in the management of surgically excised
plasia, J Vet Intern Med 18:536–539, 2004. anal sac apocrine gland adenocarcinoma in dogs, Vet Comp Oncol
320. Wouda RM, Miller ME, Chon E, et al.: Clinical effects of vinorel- 14:67–80, 2016.
bine administration in the management of various malignant 341. Murphy S, Hayes A, Adams V, et al.: Role of carboplatin in multi-
tumor types in dogs: 58 cases (1997–2012), J Am Vet Med Assoc modality treatment of canine tonsillar squamous cell carcinoma—
246:1230–1237, 2015. a case series of five dogs, J Small Anim Pract 47:216–220, 2006.
321. Pierro JA, Mallett CL, Saba CF: Phase I clinical trial of vinorelbine 342. Charney SC, Bergman PJ, McKnight JA, et al.: Evaluation of intra-
in tumor-bearing cats, J Vet Intern Med 27:943–948, 2013. cavitary mitoxantrone and carboplatin for treatment of carcinoma-
322. Minocha A, Long BH: Inhibition of the DNA catenation activity tosis, sarcomatosis and mesothelioma, with or without malignant
of type II topoisomerase by VP16-213 and VM26, Biochem Biophys effusions: a retrospective analysis of 12 cases (1997–2002), Vet
Res Commun 122:165–170, 1984. Comp Oncol 3:171–181, 2005.